[1. Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. Alzheimer’s and Dementia 2015;11(3):332. DOI: 10.1016/j.jalz.2015.02.003.10.1016/j.jalz.2015.02.003]Search in Google Scholar
[2. Saloni Tanna, 2004 Background Paper 6.11. Alzheimer Disease and other Dementias. Last updated February 20, 2013. Available at http://www.who.int/medicines/areas/priority_medicines/BP6_11Alzheimer.pdf.10.22233/20412495.0613.11]Search in Google Scholar
[3. Alzheimer Europe. The prevalence of Alzheimer in Europe. Available at: http://www.alzheimer-europe.org/Policyin-Practice2/Country-comparisons/The-prevalence-ofdementia-in-Europe. Last update: February 24, 2014.]Search in Google Scholar
[4. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frolich L, et al. The future of Alzheimer’s disease: the next 10 years. Prog Neurobiol. 2011 Dec; 95(4):718-28. DOI: 10.1016/j.pneurobio.2011.11.008.10.1016/j.pneurobio.2011.11.008]Search in Google Scholar
[5. Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer Disease. Ann Neurol. 2014 Aug; 76(2):185-205. DOI: 10.1002/ana.24188.10.1002/ana.24188]Search in Google Scholar
[6. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PIB PET assessment of change in fibrillary amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending- dose study. Lancet Neurol. 2010 Apr; 9(4):363-72. DOI: 10.1016/S1474-4422(10)70043-0.10.1016/S1474-4422(10)70043-0]Search in Google Scholar
[7. Karran E, Hardy J. Antiamyloid therapy for Alzheimer’s disease - are we on the right road? N Engl J Med. 2014 Jan 23; 370(4):377-8. DOI: 10.1056/NEJMe1313943.10.1056/NEJMe131394324450897]Search in Google Scholar
[8. Bier JC. Biomarkers of Alzheimer’s disease: concepts and clinical case. Rev Med Brux. 2013 Sep. 34(4):306-10.]Search in Google Scholar
[9. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May; 7(3):263-9. DOI: 10.1016/j.jalz.2011.03.005.10.1016/j.jalz.2011.03.005331202421514250]Search in Google Scholar
[10. Kuwano R, Hara N. Personal genomics for Alzheimer’s disease. Brain Nerve. 2013 65(3):235-46.]Search in Google Scholar
[11. Ridge PG, Mukherjee S, Crane PK, Kauwe JS; Alzheimer’s Disease Genetics Consortium. Alzheimer’s disease: analyzing the missing heritability. PLoS One. 2013 Nov 7;8(11):e79771. DOI: 10.1371/journal. pone.0079771.]Search in Google Scholar
[12. Henriksen K, O’Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, et al. The future of bloodbased biomarkers for Alzheimer’s disease. Alzheimers Dement. 2014 Jan; 10(1):115-131. DOI: 10.1016/j. jalz.2013.01.013.]Search in Google Scholar
[13. Chalbot S, Zetterberg H, Blennow K, Fadby T, Andreasen N, Grundke-Igbal I, et al. Bloodcerebrospinal fluid barrier permeability in Alzheimer’s disease. J Alzheimers Dis. 2011; 25(3):505-15.10.3233/JAD-2011-101959313945021471645]Search in Google Scholar
[14. Teng E, Chow N, Hwang KS, Thompson PM, Gylys KH, Cole GM, et al. Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer’s disease neuroimaging initiative cohort. Dement Geriatr Cogn Disord. 2015; 39(3-4):154-66. DOI: 10.1159/000368982.10.1159/000368982432393225547651]Search in Google Scholar
[15. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology. 2011 Mar 22; 76(12):1091-8. DOI: 10.1212/WNL.0b013e318211c352.10.1212/WNL.0b013e318211c35221422459]Search in Google Scholar
[16. Guo LH, Alexopoulos P, Wagenpfeil S, Kurz A, the Alzheimer’s Disease Neuroimaging Inititative, Perneczcky R. Plasma proteomics for the identification of Alzheimer’s disease. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):10. DOI: 10.1097/ WAD.0b013e31827b60d2.10.1097/WAD.0b013e31827b60d2362673823314060]Search in Google Scholar
[17. Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C. Analysis of 27 vascular related proteins reveals that NT-proBNP is a potenatial biomarker for Alzheimer’s disease and mild cognitive impairment: a pilot-study. Exp Gerontol. 2014 Feb; 50:114-21. DOI: 10.1016/j.exger.2013.12.001.10.1016/j.exger.2013.12.001431283724333505]Search in Google Scholar
[18. Behnam S, A van Buchem M, JM de Craen A, Sigurdsson S, Zhang Q, Harris TB, et al. N-terminal pro-brain natriuretic peptide and abnormal brain aging. Neurology. 2015 Sept 1; 85(9):813-820. DOI: 10.1212/ WNL.0000000000001885.10.1212/WNL.0000000000001885455302326231259]Search in Google Scholar
[19. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, et al. Plasma multyanalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012 Aug 28; 79(9):897-905. DOI: 10.1212/WNL.0b013e318266fa70.10.1212/WNL.0b013e318266fa70342584422855860]Search in Google Scholar
[20. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012 Oct; 69(10):1318-25. DOI: 10.1001/archneurol.2012.1282.10.1001/archneurol.2012.1282628760622801742]Search in Google Scholar
[21. Bjorkgvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s disease. PLoS One. 2012. 7(1): e29868. DOI: 10.1371/journal. pone.0029868.]Search in Google Scholar
[22. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med. 2007 Nov; 13(11):1359-62. DOI: 10.1038/nm1653.10.1038/nm165317934472]Search in Google Scholar
[23. Hertze J, Nagga K, Minthon L, Hansson O. Changes in cerebrospinal fluid and blood plasma levels of IGFII and its binding proteins in Alzheimer’s disease: an observational study. BMC Neurol. 2014 Apr 1; 14:64. DOI: 10.1186/1471-2377-14-64.10.1186/1471-2377-14-64397383624685003]Search in Google Scholar
[24. Sotolongo-Grau O, Pesini P, Valero S, Lafuente A, Buendia M, Perez-Grijalba V, et al. Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volume. Alzheimers Res Ther. 2014; 6(5):56. DOI: 10.1186/s13195-014-0056-3.10.1186/s13195-014-0056-3425552625484928]Search in Google Scholar
[25. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: a multicenter study with multiplexing. Exp Neurol. 2010 Jun; 223(2):366-70. DOI: 10.1016/j.expneurol.2009.07.024.10.1016/j.expneurol.2009.07.02419664622]Search in Google Scholar
[26. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, et al. Plasma amyloid-beta as a biomarker in Alzheimer’s disease: AIBL study of aging. J Alzheimers Dis. 2010; 20(4):1233-42.10.3233/JAD-2010-09024920413897]Search in Google Scholar
[27. Cosentino SA, Stern Y, Sokolov E, Scarmeas N, Manly JJ, Tang MX, et al. Plasma β-amyloid and cognitive decline. Arch Neurol. 2010; 67(12):1485-90. DOI: 10.1001/archneurol.2010.189.10.1001/archneurol.2010.189]Search in Google Scholar
[28. Laske C, Sopova K, Gkotsis C, Eschweiler GW, Straten G, Gawaz M, et al. Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer’s disease patients. J Alzheimers Dis. 2010; 21(4):1263-9.10.3233/JAD-2010-100510]Search in Google Scholar
[29. Yaffe K, Weston A, Graff-Radforf NR, Satterfield S, Simonsick EM, Younkin LH, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011. 305(3):261-6. DOI: 10.1001/jama.2010.1995.10.1001/jama.2010.1995]Search in Google Scholar
[30. Van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-control study. Lancet Neurol. 2006 Aug; 5(8):655-60. DOI: 10.1016/ S1474-4422(06)70501-4.10.1016/S1474-4422(06)70501-4]Search in Google Scholar
[31. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci USA. 2008 Sep 16; 105(37):14052-7. DOI: 10.1073/ pnas.0805902105.10.1073/pnas.0805902105254457718779561]Search in Google Scholar
[32. Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X, et al. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer’s disease. J Neurosci Res. 2012 Dec; 90(12):2247-58. DOI: 10.1002/jnr.23122.10.1002/jnr.2312222987781]Search in Google Scholar
[33. Noguchi-Shinohara M, Hamaguchi T, Nozaki I, Sakai K Yamada M. Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jackob disease. J Neurol. 2011 Aug; 258(8):1464-8. DOI: 10.1007/s00415-011-5960-x.10.1007/s00415-011-5960-x21360196]Search in Google Scholar
[34. Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, et al. Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther. 2013; 5(2):9. DOI: 10.1186/alzrt163. 10.1186/alzrt163370701523551972]Search in Google Scholar
[35. Randall J, Mortberg E, Provuncher GK, Fournier DR, Duffy DC, Rubertsson S, et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation. 2013 Mar; 84(3):351-6. DOI: 10.1016/j. resuscitation.2012.07.027.]Search in Google Scholar
[36. Liliang PC, Liang CL, Weng HC, Lu K, Wang KW, Cheng HJ, et al. Tau proteins in serum predict outcome after severe traumatic brain injury. J Surg Res. 2010 May 15; 160(2):302-7. DOI: 10.1016/j.jss.2008.12.022.10.1016/j.jss.2008.12.02219345376]Search in Google Scholar
[37. Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, et al. Altered lysosomal proteins in neural- derived plasma exosomes in preclinical Alzheimer disease. Neurology. 2015 July 7; 85(1):40-47. DOI: 10.1212/WNL.0000000000001702.10.1212/WNL.0000000000001702450194326062630]Search in Google Scholar
[38. Zarrouk A, Riedinger JM, Ahmed SH, Hammami S, Chaabane W, Debbabi M, et al. Fatty acid profiles in demented patients: identification of hexacosanoic Acid (c26:0) as a blood lipid biomarker of dementia. J Alzheimers Dis.2015; 44(4):1349-59.10.3233/JAD-14204625428249]Search in Google Scholar
[39. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, et al. Metabolomics in early Alzheimer’s disease: identification of altered plasma shpingolipidome using shotgun lipidomics. PLoS One. 2011; 6(7):e21643. DOI: 10.1371/journal.pone.002164310.1371/journal.pone.0021643313692421779331]Search in Google Scholar
[40. Mielke MM, Haughey NJ, Bandaru VV, Weinberg DD, Darby E, Zaidi N, et al. Plasma sphiengomyelins are associated with cognitive progression in Alzheimer’s disease. J Alzheimers Dis. 2011; 27(2):259-69.10.3233/JAD-2011-110405321819821841258]Search in Google Scholar
[41. Jerneren F. Brain atrophy in cognitively impaired elderly: the importance of long-chain omega-3 fatty acids and B vitamin status in a randomized controlled trial. Am J Clin Nutr. 2015. doi: 10.3945/ajcn.114.103283. DOI: 10.3945/ajcn.114.103283.10.3945/ajcn.114.10328325877495]Search in Google Scholar
[42. Baierle M, Vencato PH, Oldenburg L, Bordingnon S, Zibetti M, Trentini CM, et al. Fatty acid status and its relationship to cognitive decline and homocysteine level in the elderly. Nutrients. 2014 Sep 12; 6(9):3624-40. DOI: 10.3390/nu6093624.10.3390/nu6093624417917925221976]Search in Google Scholar
[43. Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxen Irving G, Eriksdotter M, et al. Transfer of omega-e fatty acids across the blood-brain barrier after dietary supplementation with docosahexanoic acid-rich amega-3 fatty acid preparation in patients with Alzheimer’s disease: the OmegAD study. J Intern Med. 2014 Apr; 275(4):428-36. DOI: 10.1111/joim.12166.10.1111/joim.1216624410954]Search in Google Scholar
[44. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014 Apr; 20(4):415-8. DOI: 10.1038/nm.3466.10.1038/nm.3466536046024608097]Search in Google Scholar